Skip to content

Efficacy of botulinum toxin A for the management of melasma: A split-face, randomized control study

Efficacy of botulinum toxin A for the management of melasma: A split-face, randomized control study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20240721002
Enrollment
30
Registered
2024-07-21
Start date
2023-08-08
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clinical diagnosis of melasma with symmetrical involvement of both malar areas Melasma

Interventions

The study was conducted using a split-face randomization method. One side of each patient&#039
s face received treatment with TCC alone (monotherapy).,The study was conducted using a split-face randomization method. The other side was treated with a combination of intradermal incobotulinum toxi
Active Comparator Drug,Experimental Drug
Monotherapy,Combined therapy

Sponsors

Division of Dermatology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 62 Years

Inclusion criteria

Inclusion criteria: 1. Age more than or equal to 18 years 2. Clinical diagnosis of melasma with symmetrical involvement of both malar areas 3. Willingness to comply with the study protocol and follow-up visits

Exclusion criteria

Exclusion criteria: 1. Active skin infection or inflammation at the treatment sites 2. Open wounds at the treatment sites 3. Known allergy to study medications 4. Neuromuscular disorders 5. Uncontrolled acne vulgaris 6. History of recurrent herpes infection 7. Use of topical melasma treatments within 1 month or systemic/injectable treatments within 3 months 8. Facial procedures (laser, dermabrasion, peeling, radiofrequency, micro-focused ultrasound) within 6 months 9. Facial botulinum toxin injections within 6 months 10. pregnancy or lactation

Design outcomes

Primary

MeasureTime frame
Efficacy of botulinum toxin A for the management of melasma Evaluation at 0, 2, 4, 8, 12, 16, 20 and 24 weeks Visia, Antera 3D, Colorimeter, MASI score on malar area (MASIm), GAIS score, and patient satisfaction

Secondary

MeasureTime frame
Efficacy of botulinum toxin A for a beneficial effect in melasma treatment and prevention of melasma recurrence Evaluation at 0, 2, 4, 8, 12, 16, 20 and 24 weeks Visia, Antera 3D, Colorimeter, MASI score on malar area (MASIm), GAIS score, and patient satisfaction

Countries

Thailand

Contacts

Public ContactSasipim Chaijaras

Faculty of Medicine Ramathibodi Hospital, Mahidol University

sasipimcc@gmail.com0869623242

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026